Xiaoya Liu

Dr. Xiaoya Liu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
JLJianquan Li
Jianquan Li
YHYongyang He
Yongyang He
XLXi Lei
Xi Lei
ZCZhongqiang Cao
Zhongqiang Cao
YLYuwei Liao
Yuwei Liao
XLXiaoya Liu
Xiaoya Liu
Background: Antimicrobial agents’ wastage is a huge problem, especially for pediatric patients, resulting in excessive drug expenditure and increasing the economic burden on patients’ families. Moreover, the cost of disposing of antimicrobial agents’ waste and the risk of environmental and occupational exposure also increased. This study aimed to explore the cost-effectiveness of the vial-sharing strategy combined with the daily-rate charge mode for pediatric inpatients to provide a strategy for reducing patients’ expenditures, saving medical costs, and reducing drug proportion. Methods: This retrospective study was conducted at Pharmacy Intravenous Admixture Service (PIVAS), Shenzhen Children’s Hospital, Guangdong Province, China, in 2022. Data on prescription drugs were collected from the PIVAS system. Ten antimicrobial drugs with a frequency of prescriptions no less than twice once daily were selected, and the drug costs, drug weight, and drug saved were further analyzed according to the combination of real-time vial sharing strategy and daily-rate charge mode. Traditional single vial charge mode without vial sharing was set as a control strategy. The actual expenditure of the hospital was also calculated and analyzed. Results: During 2022, ¥ 4,122,099 (34.4%) was saved for inpatients by applying a vial-sharing strategy on ten antibacterial agents, and more than 46,343,750 mg (24.6%) of drugs were totally saved. The top 5 drugs saved by the real-time vial-sharing strategy were cefoperazone-sulbactam, vancomycin, amoxicillin-sulbactam, ceftazidime, and meropenem. Taken the price into consideration, the top five payment-saved drugs were vancomycin (¥ 1,522,385), meropenem (¥ 1,311,475), cefoperazone-sulbactam (¥ 736,697), imipenem-cilastatin (¥ 406,092), and amoxicillin-sulbactam (¥ 51,394). Moreover, the account balance of the hospital was up to ¥ 426,499. Conclusion: The real-time vial sharing strategy combined with the daily-rate charge mode greatly reduces drug wastage and patients’ payments. It may be useful for hospitals with PIVAS to achieve vial-sharing while protecting the best interest of inpatients.

3 December 2025 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
ZCZhongqiang Cao
Zhongqiang Cao
JCJunjie Cheng
Junjie Cheng
ZCZebin Chen
Zebin Chen
XLXi Lei
Xi Lei
LYLing Yang
Ling Yang
XLXuejuan Li
Xuejuan Li
Although triptorelin acetate (TA) is generally considered a safe medication, severe adverse drug reactions (ADRs) to triptorelin have occurred. In this stu

12 January 2026 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
TLTing Liu
Ting Liu
ZCZhongqiang Cao
Zhongqiang Cao
FLFangyuan Lai
Fangyuan Lai
HXHuanli Xu
Huanli Xu
ZCZebin Chen
Zebin Chen
XLXiaoya Liu
Xiaoya Liu
Vincristine, a cornerstone vinca alkaloid in pediatric oncology, has historically been regarded as a low-risk agent for drug-induced acute pancreatitis (DIAP). We report the first documented pediatric case of vincristine monotherapy-associated acute pancreatitis, challenging existing toxicity paradigms. A 3.25-year-old boy with stage IV Wilms tumor developed acute-onset fever and localized periumbilical pain 48 h after vincristine infusion (0.9 mg), administered within standard dosing. Laboratory testing confirmed marked pancreatic hyperenzymemia (serum α-amylase 2,022 U/L, 12.5 × ULN; lipase 568 U/L, 7.1 × ULN), and contrast-enhanced ultrasonography revealed pancreatic edema. A Naranjo score of 7 indicated probable causality, further supported by complete symptom resolution after substitution with vindesine and no recurrence during six months of follow-up. Genetic testing showed no CEP72 (rs924607) susceptibility variant, suggesting a hypersensitivity rather than pharmacogenomic mechanism. This case highlights the need to re-evaluate vincristine's DIAP risk profile in children and supports implementing routine post-infusion monitoring of pancreatic enzymes in high-risk patients. Vindesine may serve as a safe and effective alternative agent. These findings underscore the importance of updating pediatric chemotherapy safety guidelines for vinca alkaloid-containing regimens.

15 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ZCZhongqiang Cao
Zhongqiang Cao
JCJunjie Cheng
Junjie Cheng
ZCZebin Chen
Zebin Chen
XLXi Lei
Xi Lei
LYLing Yang
Ling Yang
XLXuejuan Li
Xuejuan Li
Background: Although triptorelin acetate (TA) is generally considered a safe medication, severe adverse drug reactions (ADRs) to triptorelin have occurred. In this study, we present the largest retrospective analysis of ADRs related to TA during the treatment of pediatric central precocious puberty. Methods: We describe a total of 38 suspected cases of TA-induced ADRs reported to the pharma-covigilance center of Shenzhen Children’s Hospital from September 2015 to December 2022. Causality assessment was carried out using the validated Kramer’s algorithm. The severity of ADRs was evaluated using the Modified Hartwig and Siegel Scale. Results: The most common ADRs attributed to TA were damage to the cutaneous tissues (29.3%) and reactions affecting the systemic and digestive systems (20.7%). The majority (61.1%) of ADRs occurred within 2 hours of administration. Among the 12 patients with severe ADRs, the three most frequent symptoms were anaphylactic reactions, hip synovitis, and arthralgia. Additional-ly, six patients experienced ADRs due to a change in the manufacturing process. Conclusion: The majority of ADRs observed in pediatric cases were type I anaphylactic reactions, which are rare but life-threatening. It is advisable to perform skin prick tests and intradermal tests when switching pharmaceutical manufacturers.